Visual Function Measurements in Eyes With Diabetic Retinopathy: An Expert Opinion on Available Measures.

Autor:	Glassman AR; Jaeb Center for Health Research, Tampa, Florida., Elmasry MA; Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts.; Joslin Diabetes Center, Boston, Massachusetts., Baskin DE; University of Texas Health Science Center at San Antonio, San Antonio, Texas., Brigell M; Consultant, Belmont, Massachusetts., Chong V; UCL Institute of Ophthalmology, London, UK., Davis Q; LKC Technologies, Inc, Gaithersburg, Maryland., Lesmes L; Adaptive Sensory Technology, San Diego, California., Levin LA; Departments of Ophthalmology & Visual Sciences and Neurology & Neurosurgery, McGill University, Montreal, Canada., Maddess T; John Curtin School of Medical Research, Australian National University, Canberra, Australian Capital Territory, Australia., Taylor LJ; Nuffield Laboratory of Ophthalmology, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK., Wenzel A; Roche Pharma Research & Early Development, F. Hoffmann - La Roche Ltd, Basel, Switzerland.
Jazyk:	angličtina
Zdroj:	Ophthalmology science [Ophthalmol Sci] 2024 Apr 06; Vol. 4 (5), pp. 100519. Date of Electronic Publication: 2024 Apr 06 (Print Publication: 2024).
DOI:	10.1016/j.xops.2024.100519
Abstrakt:	Clinical Relevance: Visual function impairment from diabetic retinopathy can have a considerable impact on patient's quality of life. Best-corrected visual acuity (BCVA) is most commonly used to assess visual function and guide clinical trials. However, BCVA is affected late in the disease process, is not affected in early disease, and does not capture some of the visual disturbances described by patients with diabetes. The goal of this report is to evaluate the relationship between diabetic retinal disease (DRD) and visual function parameters to determine which if any of them may be used in a future DRD staging system. Methods: The visual functions working group was 1 of 6 areas of DRD studied as part of the DRD staging system update, a project of the Mary Tyler Moore Vision Initiative. The working group identified 12 variables of possible interest, 7 of which were judged to have sufficient preliminary data to suggest an association with DR to warrant further review: microperimetry, static automated perimetry, electroretinogram (ERG) oscillatory potentials, flicker ERG, low luminance visual acuity (LLVA), contrast sensitivity (CS), and BCVA. The objective field analyzer (OFA) was added after subsequent in-person workshops. Results: Currently, the only visual function test available for immediate use is BCVA; the remaining tests are either promising (within 5 years) or have potential (>5 years) use. Besides BCVA, most visual function tests had a limited role in current clinical care; however, LLVA, CS, flicker ERG, and OFA demonstrated potential for screening and research purposes. Conclusions: Although current visual function tests are promising, future prospective studies involving patients with early and more advanced retinopathy are necessary to determine if these tests can be used clinically or as endpoints for clinical studies. Financial Disclosures: Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article. (© 2024 by the American Academy of Ophthalmology.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu